drugset / Trial / NCT02077777

Chemopreventive Action of Mesalazine on Colorectal Cancer: a Pilot Study for an "in Vivo" Evaluation of the Molecular Effects on β-catenin Signaling Pathway.

NCT02077777

Phase 2 Completed 21 enrolled SOFAR S.p.A.
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to obtain an "in vivo" confirmation that mesalazine induces the gene expression of μ-protocadherin and other related genes in the colon mucosa, as demonstrated in some "in vitro" experiments. .

Timeline

Start
2012-10
Primary completion
2016-06
Completion
2016-06

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Mesalamine Small molecule 800 mg Oral

Indications